OPZELURA (ruxolitinib cream) has shown strong market growth, driven by increasing adoption in dermatological conditions like vitiligo and atopic dermatitis. Its unique positioning as the first ...
Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting ...
One poster will share pooled INTEGUMENT data of ZORYVE® (roflumilast) cream 0.15% in atopic dermatitis (AD) in patients with prior inadequate response, intolerance, and/or contraindications to topical ...
Clinical phenotypes of atopic dermatitis can vary greatly based on skin color and can make atopic dermatitis difficult to diagnose.
Topical roflumilast, 0.05%, is under consideration for treating mild to moderate atopic dermatitis in children aged 2-5 years ...
This once-daily topical treatment is the latest phosphodiesterase-4 (PDE4) inhibitor designed for mild to moderate atopic ...
The FDA has accepted the supplemental new drug application for Zoryve cream 0.05% to treat mild to moderate atopic dermatitis ...
ZORYVE's rapid sales growth positions Arcutis Biotherapeutics as a strong buy with profitability expected in 12 months. Read ...
According to a Phase 3 clinical trial (INTEGUMENT-PED) roflumilast cream 0.05% is effective and safe for children aged 2-5 ...
Arcutis Biotherapeutics (ARQT) announced that Pediatric Dermatology published online positive results from INTEGUMENT-PED, the pivotal phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback